World Botulinum Toxin Market

World Botulinum Toxin Market

This report analyzes the worldwide markets for Botulinum Toxin in Millions of US$. The end-use segments analyzed are Cosmetic Applications, and Therapeutic Applications. The report provides separate comprehensive analytics for the USA, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 15 companies including many key and niche players worldwide such as Allergan, Inc., Ipsen Group, Metabiologics, Inc., Merz Pharmaceuticals GmbH, Mentor Corporation, and Solstice Neurosciences, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

BOTULINUM TOXIN MCP-1833
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Product Definitions and Scope of Study I-3
Cosmetic Applications I-3
Therapeutic Applications I-3


II. EXECUTIVE SUMMARY

1. Industry Overview II-1
‘Bright’ Outlook Forecast for Botulinum Toxin II-1
Growth Drivers for Botulinum Toxin II-1
Market Dynamics II-1
Combination Therapy Supports Market Growth II-1
Botulinum Toxin and Soft Tissue Filling Agents II-2
Botulinum Toxin Injections and Laser Resurfacing II-2
Botulinum Toxin and Phenol II-2
Technological Innovations Drive Botulinum Market II-2
Changing Consumer Belief II-3
Under-Treated Diseases Boost Demand for Off- Label Products II-3
Burgeoning Consumer Awareness II-3
‘Feeling’ to Look Good - Driving Aesthetic Market II-3
Expansion of Financing Services to Propel Growth II-3
Adverse Effects Impedes Market Growth II-3
High Cost - A Major Market Restraint II-4
Concern over Long-Term Side Effects II-4

2. Competitive Landscape II-5
Allergan Dominates Global Botulinum Toxin Market II-5
Table 1: Revenues of Allergan, Inc (2001-2005): Net Sales of
Botox®/Neuromodulator(In US$ Million) (includes corresponding
Graph/Chart) II-5
Botox Dominance Remains Stable in the Global Market II-6
Clinical Trails in Progress for Botox II-6
Ipsen - Major Player in Botulinum Toxin Market II-6
Table 2: Revenues of Ipsen Group (2004 & 2005): Net Sales of
Dysport® (In € Million) II-6
Clinical Trails in Progress for Dysport II-7
Solstice - Only Global Manufacturer of Type B Botulinum Toxin II-7
Table 3: Leading Players in Global Botulinum Toxin
(Therapeutic) Market (2005): Percentage Breakdown by Revenues
for Allergan (Botox®), Solstice (Myobloc®), Ipsen and
(Dysport®) (includes corresponding Graph/Chart) II-7

Table 4: Leading Players in Global Botulinum Toxin (Cosmetic)
Market (2005): Percentage Breakdown by Revenues for Allergan
(Botox®), Ipsen (Dysport®/Reloxin®), and Others (includes
corresponding Graph/Chart) II-7
Worldwide Botulinum Toxin Market (2005): Competitors Profile
of the Top 2 Companies II-8
Comparison of Allergan’s Botox® and Ipsen’s Reloxin® II-8
Table 5: Worldwide Botulinum Toxin Market (2005 & 2006):
Percentage Breakup by Key Products - Botox®, Dysport®,
Myobloc®, and Others® (includes corresponding Graph/Chart) II-9

3. Product Overview II-10
Botulinum Toxin - An Introduction II-10
Chemical Overview II-11
Mechanism of Botulinum Toxin II-11
Side Effects II-11
Immunogenicity Effects Response to Botulinum Therapy II-12
A Peek into the History and Development II-12
Botulinum Toxin - A Classification II-13
Botulinum Toxin Type A II-13
Botox® II-13
Historical Timeline of Botox: 1885-2002 II-14
Botox Approvals and Indications in Select Global Regions II-15
Dysport® II-15
Xeomin® II-15
Botulinum Toxin Type B II-15
Myobloc® II-16
Key Products in Botulinum Toxin Type A, Type B II-16
Competitive Overview of Botox® - Cosmetic Purpose (
Smoothing of Facial Wrinkles) II-17
Other Types II-17
Applications of Botulinum Toxin II-17
Botulinum - Toxin or Treatment? II-17
Therapeutic Applications of Botulinum Toxin II-18
Botulinum Toxin for Movement Disorders II-18
Botulinum Toxin Cures Dystonia II-18
Botulinum is Beneficial for Cervical Dystonia II-19
Botulinum Toxin Cures Laryngeal Dystonia II-19
Ease from Writer’s Cramp II-19
Botulinum - Useful To Treat Oromandibular Dystonia II-20
Tics II-20
Tremors II-20
Parkinson's Disease II-20
Botulinum Toxin Treats Hemifacial Spasm II-20
Is Botulinum Toxin an Answer to Blepharospasm? II-21
Tantalizing Effect in Strabismus II-21
Childhood Strabismus II-21
Botulinum Toxin Helps Spasticity Cure Better II-22
Stroke II-22
Traumatic Brain Injury II-22
Cerebral Palsy II-22
Multiple Sclerosis II-23
Botulinum Toxin Soothes Pain II-23
Botulinum Heals Hypertonic Disorders II-23
Cosmetic Applications of Botulinum Toxin II-24
Botulinum Toxin Irons Out Facial Wrinkles II-24
Botulinum Lessens Facial Scarring II-25
Botulinum Toxin (Botox) Users Becoming Addictive II-25
Key Cosmetic Indications for Botulinum Toxin II-25
Additional Applications II-26
Positive Response of Rigid Spine Syndrome to Botulinum Toxin II-26
Botulinum Toxin Effective in Bladder Dysfunctions II-26
Botox Provides Respite from Tinnitus II-27
Botulinum Toxin for Anal Fissure II-27
Can Botox Prevent Baldness? II-27
Refractory Vaginismus and Botulinum II-27
Botulinum Toxin Helps to Cure Dysphagia II-28
Encouraging Effects of Botox in Migraine II-28
Botulinum Eases Severe Facial Pain II-28
Botulinum Provides Relief from Pelvic Floor Pain II-28
Botox Can Treat Children with Non-Neurogenic, Neurogenic
Bladder II-29
Botulinum Toxin Finds Application in Cancer Treatment II-29
Botox Can Reduce Pain, Itching and Hand Eczema II-29
Botulinum Reduces Plantar Fasciitis Pain II-29
Botox Helps to Treat Carpal Tunnel Syndrome II-29
Other Indications for Botulinum Toxin II-30
Terrorist and Military Exploitation of Botulinum Toxin II-30
Botulism - Infection from Botulinum II-30
Types of Botulism II-31
Classical or Food Borne Botulism II-31
Home Canning - Culprit Behind Botulism II-31
Wound Botulism II-32
Infant Botulism II-32
Botulism Outbreak in Animals II-32
Safety Precautions II-33
Medicinal Investigations II-33
Vaccine for Botulinum Toxin II-34
Technological Development II-34
US Inventor Develops New Fermentation Process II-34

4. Recent Industry Activity II-35
Allergan and Clinique Form Strategic Collaboration II-35
Ipsen and Medicis File BLA for Reloxin® II-35
Medicis Plans Investment in Revance II-35
Galderma Receives Distribution Rights for Dysport (R) II-35
Allergan to Acquire Espirit Pharma II-35
Allergan Launches "Project: Sweat Free" II-36
Solstice Neurosciences Inks Commercialization Agreement II-36
Ipsen Partners with Galderma II-36
Allergan Rolls Out New Division with Acquisition of Inamed II-36
FTC Mandates Allergan Divest Rights to Reloxin II-36
Medicis Inks Agreement with Ipsen II-36
Solstice Neurosciences Inks Licensing Agreement with DreamPharma II-37
Botox Enters India Market II-37
Mentor Begins Phase-I Clinical Trial on Botulinum Toxin II-37
Allergan Inks Agreement with GlaxoSmithKline II-37
DOR BioPharma Inks Agreement with Dowpharma II-38
Merz Pharma Receives Approval for Botulinum Toxin Type A II-38
Mentor Initiates Phase-I Clinical Trial II-38
Mentor Establishes New Production Facility II-38
DOR BioPharma and Thomas Jefferson University Teams-Up with US
Army II-38
Mentor Inks Licensing Agreement with WARF II-39
Solstice Acquires World Rights for Myobloc II-39
Inamed Rolls Out Reloxin Brand II-39

5. Focus on Select Key Players II-40
Allergan, Inc (USA) II-40
Ipsen Group (France) II-40
Metabiologics Inc, (USA) II-40
Merz Pharmaceuticals GmbH (Germany) II-41
Mentor Corporation (USA) II-41
Solstice Neurosciences, Inc. (USA) II-41

6. Global Market Perspective II-42
Table 6: World Recent Past, Current & Future Analysis for
Botulinum Toxin by Geographic Region - US and Rest of World
Independently Analyzed by Annual Sales in US$ Million for the
Years 2000 through 2010 (includes corresponding Graph/Chart) II-42

Table 7: World Long-term Projections for Botulinum Toxin by
Geographic Region - US and Rest of World Independently
Analyzed by Annual Sales in US$ Million for the Years 2011
through 2015 (includes corresponding Graph/Chart) II-42

Table 8: World 10-Year Perspective for Botulinum Toxin by
Geographic Region - Percentage Breakdown of Dollar Sales for
US and Rest of World for the Years 2003, 2008 & 2012 II-43

Table 9: World Recent Past, Current & Future Analysis for
Botulinum Toxin in Cosmetic Applications by Geographic Region
- US and Rest of World Independently Analyzed by Annual Sales
in US$ Million for the Years 2000 through 2010 (includes
corresponding Graph/Chart) II-44

Table 10: World Long-term Projections for Botulinum Toxin in
Cosmetic Applications by Geographic Region - US and Rest of
World Independently Analyzed by Annual Sales in US$ Million
for the Years 2011 through 2015 (includes corresponding
Graph/Chart) II-44

Table 11: World 10-Year Perspective for Botulinum Toxin in
Cosmetic Applications by Geographic Region - Percentage
Breakdown of Dollar Sales for US and Rest of World for the
Years 2003, 2008 & 2012 II-45

Table 12: World Recent Past, Current & Future Analysis for
Botulinum Toxin in Therapeutic Applications by Geographic
Region - US and Rest of World Independently Analyzed by Annual
Sales in US$ Million for the Years 2000 through 2010 (includes
corresponding Graph/Chart) II-46

Table 13: World Long-term Projections for Botulinum Toxin in
Therapeutic Applications by Geographic Region - US and Rest of
World Independently Analyzed by Annual Sales in US$ Million
for the Years 2011 through 2015 (includes corresponding
Graph/Chart) II-46

Table 14: World 10-Year Perspective for Botulinum Toxin in
Therapeutic Applications by Geographic Region - Percentage
Breakdown of Dollar Sales for US and Rest of World for the
Years 2003, 2008 & 2012 II-47


III. MARKET

1. The United States III-1
A.Market Analysis III-1
Botulinum Toxin Market to Grow at a Healthy Rate III-1
Botox Leads the US Botulinum Toxin Market III-1
Botox Growth - Largely Supported by FDA Approval for
Cosmetic Use III-1
Botox Approvals and Indications in the US III-2
Market Dynamics III-2
Booming Non-Surgical Treatments III-2
Aging Baby Boomers Drive Aesthetic Business III-2
Increasing Physician Base Impels Botulinum Market III-2
Direct-to-Consumer Advertising Drive Cosmetic Botulinum Toxin III-3
Increasing Off-label Use of Botulinum Toxin III-3
Medical Spas - Growing in Number III-3
Heightened Competition Limits Growth III-3
Arduous Regulations Deter Product Progress III-4
Botulism Poisoning - A Major Concern III-4
Botox Injection - Popular Non-Invasive Cosmetic Procedure III-4
Table 15: Number of Botox Injections (2000-2005) (includes
corresponding Graph/Chart) III-5
Table 16: Botox Injections by Gender (2004) III-5
Table 17: Botox Injections by Age Group (2004) (includes
corresponding Graph/Chart) III-5
Botox Attracts American Men III-6
Table 18: Non-Invasive Cosmetic Procedures in the US
(2005): Percentage of Patients Treated by All US-Based
AACS Members Practices (includes corresponding
Graph/Chart) III-6

Table 19: Cosmetic Procedures (Surgical/Non-Surgical) in
the US (2005): Percentage of Patients Treated by All
US-Based AACS Members Practices III-6
Factors to be Considered Prior to Cosmetic Botox Treatment III-7
Botox for Spasticity - Improved Quality of Life III-7
Coding and Reimbursement III-7
US Cosmetic Market - Statistical Data III-8
Table 20: Cosmetic Market in the US (2004 & 2005): Leading
Surgical Procedures (includes corresponding Graph/Chart) III-8
Table 21: Cosmetic Market in the US (2004 & 2005): Leading
Non-Surgical Procedures (includes corresponding Graph/
Chart) III-9
Table 22: Number of Cosmetic Procedures in the US (2005):
Percentage Breakdown by Gender III-9
Table 23: Number of Cosmetic Procedures in the US (2005):
Percentage Breakdown by Age Group (includes corresponding
Graph/Chart) III-9

Table 24: Number of Cosmetic Procedures in the US (2005):
Percentage Breakdown by Facility (includes corresponding
Graph/Chart) III-10

Table 25: Cosmetic Market in the US (2004): Percentage
Breakdown by Procedure Type III-10
Technological Development III-10
Strategic Corporate Developments III-10
Key Players III-14
B.Market Analytics III-16
Table 26: US Recent Past, Current & Future Analysis for
Botulinum Toxin by Application - Cosmetic Applications and
Therapeutic Applications Independently Analyzed by Annual
Sales in US$ Million for the Years 2000 through 2010
(includes corresponding Graph/Chart) III-16

Table 27: US Long-term Projections for Botulinum Toxin by
Application - Cosmetic Applications and Therapeutic
Applications Independently Analyzed by Annual Sales in US$
Million for the Years 2011 through 2015 (includes
corresponding Graph/Chart) III-16

Table 28: US 10-Year Perspective for Botulinum Toxin -
Percentage Breakdown of Dollar Sales for Cosmetic
Applications and Therapeutic Applications for the Years
2003, 2008 & 2012 III-17

2. Rest of World III-18
A.Market Analysis III-18
Current and Future Analysis III-18
Europe III-18
Botox Demand Increases with Zeal For Beauty III-18
Botox Approvals and Indications in Select European Countries III-18
Botox to Support Radiation Treatments III-19
Asia III-19
India - An Emerging Market for Botox III-19
Korea - Fast Catching Up the Trend III-19
Australia - A Well Supported Market III-19
Botox Approvals and Indications in Select Asian Countries III-20
Botox Approvals and Indications in Select Latin American
Regions III-20
Botox Approvals and Indications in Other Select Global
Regions III-21
Strategic Corporate Developments III-21
Key Players III-22
B.Market Analytics III-23
Table 29: Rest of World Recent Past, Current & Future
Analysis for Botulinum Toxin by Application - Cosmetic
Applications and Therapeutic Applications Independently
Analyzed by Annual Sales in US$ Million for the Years 2000
through 2010 (includes corresponding Graph/Chart) III-23

Table 30: Rest of World Long-term Projections for Botulinum
Toxin by Application - Cosmetic Applications and Therapeutic
Applications Independently Analyzed by Annual Sales in US$
Million for the Years 2011 through 2015 (includes
corresponding Graph/Chart) III-24

Table 31: Rest of World 10-Year Perspective for Botulinum
Toxin - Percentage Breakdown of Dollar Sales for Cosmetic
Applications and Therapeutic Applications for the Years
2003, 2008 & 2012 III-24


IV. COMPETITIVE LANDSCAPE